Glucagonoma

This is a rare type of cancer that starts in the pancreas. It makes too much glucagon, a hormone that raises blood sugar. People with this cancer often lose weight, get sores in their mouth and tongue, and have a specific skin rash called migratory erythema. It's usually a serious condition.

Condition

What people with Glucagonoma report

Every report comes from a Lived member, sent anonymously.

Have you tried Octreotide for Glucagonoma?

NameHow it went

About Glucagonoma

What It Is

Glucagonoma is a rare tumor of the pancreas that grows from alpha cells, the cells that make the hormone glucagon. Glucagon normally raises blood sugar between meals by signaling the liver to release stored sugar and to break down protein for fuel. A glucagonoma releases glucagon continuously and in large amounts, which pushes blood sugar up and keeps the body in a steady state of breakdown that uses up protein, zinc and essential fats. That hormone excess produces a recognizable pattern called glucagonoma syndrome. Its most distinctive feature is a painful, itchy rash called necrolytic migratory erythema: red patches that blister, crust and peel, often around the groin, buttocks, thighs, lower legs and mouth, healing in one spot as they appear in another. Diabetes or high blood sugar, weight loss, anemia (a low red blood cell count), a sore red tongue or cracked corners of the mouth, diarrhea, blood clots in the veins and changes in mood such as depression can also occur. Glucagonoma is a type of pancreatic neuroendocrine tumor, a group of hormone-cell tumors that behave quite differently from the more common form of pancreatic cancer. It usually grows slowly, but most glucagonomas are cancerous and can spread. Because the early signs are easily mistaken for other problems, the tumor has often already reached the liver by the time it is found, which is why recognizing the pattern early matters.

Causes & Risk Factors

Most glucagonomas develop for no known reason, and nothing a person did is known to cause one. A minority are inherited as part of a genetic syndrome, most often multiple endocrine neoplasia type 1 (MEN1), which causes tumors in several hormone-producing glands, including the parathyroid glands, the pituitary gland and the pancreas. Von Hippel-Lindau syndrome and a very rare change in the glucagon receptor gene (Mahvash disease) are other inherited causes. Glucagonoma is usually diagnosed in middle age, at an average age of around 50, and affects men and women about equally. A personal or family history of MEN1 is the main known risk factor and a reason to discuss genetic counseling.

How It's Diagnosed

The path to diagnosis often starts with the skin. The rash is commonly treated as eczema or another dermatitis before anyone suspects a tumor, and in published cases the diagnosis came on average about three years after the first symptoms. The combination that should raise suspicion is a stubborn, migrating, blistering rash together with weight loss, new or worsening diabetes, or anemia. The key blood test is the glucagon level. In glucagonoma it is usually far above normal, often above about 500 pg/mL (picograms per milliliter). A milder rise has many other explanations, including liver cirrhosis, kidney failure, pancreatitis and diabetes itself, so a modest result does not establish the diagnosis on its own. Blood tests often also show high blood sugar, anemia and low levels of zinc and amino acids (the building blocks of protein). Imaging then looks for the tumor and any spread. A CT scan or MRI of the abdomen usually finds it, most often in the body or tail of the pancreas. Endoscopic ultrasound, in which a small ultrasound probe on a flexible scope is passed through the mouth into the stomach, can detect smaller tumors and collect a needle sample. A specialized PET scan with a tracer that attaches to somatostatin receptors (for example, a gallium-68 DOTATATE scan) shows tumor tissue elsewhere in the body and suggests whether somatostatin-based treatments are likely to work. A biopsy confirms that the tumor is neuroendocrine rather than the more common pancreatic cancer, and its grade (how quickly the cells are dividing) helps guide treatment. Because some glucagonomas are part of MEN1, doctors also ask about family history and may recommend genetic testing.

Treatment Options

Surgery to remove the tumor is the only treatment that can cure glucagonoma, and it is also the most effective way to clear the rash and other symptoms. The operation depends on where the tumor sits. For tumors in the body or tail of the pancreas, it is usually a distal pancreatectomy, which removes the tail end of the pancreas, often along with the spleen; a tumor in the head of the pancreas may need a larger operation called a Whipple procedure. Nearby lymph nodes are removed as well. When the tumor has spread to the liver, removing the liver deposits at the same time is sometimes possible, and surgery may be recommended even when not every bit of tumor can be removed, because it can relieve symptoms and improve survival. Before surgery, and whenever the tumor cannot be fully removed, an early step is usually to control the hormone's effects. Somatostatin analogs are injected medicines that mimic somatostatin, a natural hormone that switches off glucagon release. Octreotide (Sandostatin, including a long-acting monthly form) and lanreotide (Somatuline Depot) often improve the rash and weight loss and may also slow tumor growth. Common side effects include diarrhea, stomach pain and gallstones. Rebuilding nutrition matters just as much: zinc, amino acid infusions or extra protein, and essential fatty acids help the skin heal, and high blood sugar is treated with diet, metformin or insulin as needed. Because clots are a real risk, a blood thinner such as heparin is commonly given around the time of surgery. For tumors that cannot be removed or that keep growing, several options can control the disease for a time. Liver-directed treatments block the blood supply to liver tumors through a catheter, sometimes delivering chemotherapy at the same time, or destroy them with heat. Chemotherapy, such as capecitabine with temozolomide or a streptozocin-based combination, is another option. Everolimus (Afinitor) and sunitinib (Sutent), targeted cancer medicines approved for advanced pancreatic neuroendocrine tumors, are also used; everolimus can raise blood sugar, which matters in a condition that already does. Peptide receptor radionuclide therapy uses a somatostatin-like molecule to carry radiation directly to tumor cells that have somatostatin receptors; lutetium Lu 177 dotatate (Lutathera) is the approved form. Evidence specific to glucagonoma for each of these comes from small case series, so treatment is best planned with a team experienced in neuroendocrine tumors.

What to Expect

Glucagonoma usually grows slowly, so many people live for years, even when it has spread. Outlook depends most on whether the tumor can be completely removed. In published case collections, nearly everyone whose tumor had not spread was alive 10 years later, compared with about half of those whose tumor had spread. These figures come from small groups gathered over many years, and an individual outlook depends on the tumor's grade, how far it has spread and how it responds to treatment. After successful surgery, the rash typically fades as glucagon levels fall. Follow-up continues for years with blood tests and scans, because the tumor can return. For people living with spread disease, care tends to be long-term and steady rather than a single course: regular long-acting injections, periodic scans and glucagon measurements, attention to nutrition and blood sugar, and a change of treatment when the tumor grows or symptoms return. Weight loss, fatigue and skin flares can make work and daily routines harder during active phases. Depression and other mood changes are a recognized part of the syndrome itself, so they are worth raising with the care team rather than putting up with. People with MEN1 may need ongoing checks for tumors in the other glands it affects, and relatives may be offered testing.

When to Seek Help

Arrange a medical evaluation if a painful, blistering rash keeps moving around the body and does not respond to usual skin treatments, especially alongside unexplained weight loss, new diabetes or anemia. Mention any personal or family history of MEN1. If you have glucagonoma, call your care team right away about pain, swelling, warmth or redness in one leg, which can signal a blood clot. Let the team know, too, if blood sugar readings stay high despite treatment or if weight loss or the rash returns after a period of control. Call 911 for sudden shortness of breath, chest pain that worsens with a deep breath, coughing up blood or fainting, which can mean a clot has traveled to the lungs.

Questions to Ask Your Doctor

  1. 1.Has the tumor spread, and is surgery to remove it an option for me?
  2. 2.How will we use my glucagon level and scans to track whether treatment is working?
  3. 3.How will we control the rash, weight loss and blood sugar while we plan or wait for treatment?
  4. 4.How high is my risk of blood clots, and should I take a blood thinner?
  5. 5.Should I or my family members have genetic testing for MEN1?

Last reviewed • Oct 2026

Educational content, not medical advice.